Louisiana State University Health New Orleans, an NCI-NCORPS designated institution, and ConcertAI, LLC have formed a five-year partnership to improve the diversity of clinical trials and ensure broader clinical trial access throughout the Gulf South region.
UC San Diego has received a five-year, $16 million grant from NIH Common Fund’s Faculty Institutional Recruitment for Sustainable Transformation Program will enable the University of California San Diego to recruit 12 diverse, early-career research faculty in the biomedical sciences. This is the largest grant received by UC San Diego to enhance faculty diversity.
Sophia George was named the inaugural associate director of diversity, equity, and inclusion, and Ashish Shah was named director of clinical trials and translational research and principal investigator in the Section of Virology and Immunotherapy at Sylvester Comprehensive Cancer Center’s Brain Tumor Initiative at the University of Miami Miller School of Medicine.
The Sexual and Gender Minority Cancer Curricula to Advance Research & Education (SGM Cancer CARE) program is a three-day workshop and ten monthly seminars for early career professionals offered annually, at no cost to participants, over the next five years.
Chris Neumann was named vice president of learning and education, and Kirsta Suggs the first director of diversity, equity, and inclusion, at the American Society for Radiation Oncology.
Vetta Sanders Thompson was named the inaugural associate director of diversity, equity, and inclusion at Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital.
FDA is asking sponsors of all investigational medical products to focus on including diverse patients throughout the clinical development process.
In a panel discussion this week, four cancer centers directors described how their experiences as immigrants have shaped their approach to oncology and the U.S. healthcare system.
Ranna Parekh was named chief diversity, equity, and inclusion officer at The University of Texas MD Anderson Cancer Center, effective May 31.
After nearly five years in the federal government—at both NCI and FDA—Ned Sharpless is stepping down from his position as NCI director.
